| Literature DB >> 28802125 |
Wagdy M Eldehna1, Mahmoud F Abo-Ashour2, Alessio Nocentini3, Paola Gratteri4, Ibrahim H Eissa5, Mohamed Fares6, Omnia E Ismael7, Hazem A Ghabbour8, Mahmoud M Elaasser9, Hatem A Abdel-Aziz10, Claudiu T Supuran11.
Abstract
Herein we report the synthesis of two series of novel 4/3-((4-oxo-5-(2-oxoindolin-3-ylidene)thiazolidin-2-ylidene)amino)benzenesulfonamides (4a-m and 7a-g). All the newly prepared sulfonamides were in vitro investigated as inhibitors of the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) isoforms hCA I, II, IV and IX, using a stopped-flow CO2 hydrase assay. In particular, hCA isoforms II and IX (tumor-associated) were more susceptible to inhibition by the synthesized derivatives, with KIs in the range of 2.6-598.2 nM for hCA II, and of 16.1-321 nM for hCA IX. All compounds (4a-m and 7a-g) were evaluated for their anti-proliferative activity against breast cancer MCF-7 and colorectal cancer Caco-2 cell lines. Compound 4c was found to be the most potent derivative against MCF-7 (IC50 = 3.96 ± 0.21 μM), while 4j was the most active member against Caco-2 cells (IC50 = 5.87 ± 0.37 μM). Compound 4c induced the intrinsic apoptotic mitochondrial pathway in MCF-7 cells; evidenced by the enhanced expression of the pro-apoptotic protein Bax and the reduced expression of the anti-apoptotic protein Bcl-2, and the up-regulated active caspase-9 and caspase-3 levels.Entities:
Keywords: Anticancer; Apoptosis; Benzenesulfonamide; Carbonic anhydrase inhibitors; Isatin
Mesh:
Substances:
Year: 2017 PMID: 28802125 DOI: 10.1016/j.ejmech.2017.07.073
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514